High-precision radiosurgery followed by minimally invasive eye-sparing surgery for prominent uveal melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study prospectively evaluates modern radiation planning standards and newly adopted therapy techniques for high-prominence uveal melanoma. It uses high-resolution diagnostics and techniques such as VMAT and image-guided radiotherapy to guide treatment. The goal is to standardize treatment parameters and understand how these factors relate to long-term outcomes like overall survival and local tumor control.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Functional Resectability,
* Technical Resectability
* high-prominent uveal melanoma

Exclusion Criteria:

* EOE
* At least in part remaining eye function that can be saved

Where it's running

• Department for Radiotherapy, University Hospital Essen, National Center for Tumor Diseases (NCT) West
  Essen, Germany / NRW, Germany Recruiting
• Maja Guberina
  Essen, Germany Recruiting
• University Hospital Essen
  Essen, Germany Recruiting

Study contacts

• Study coordinator: Maja Guberina, PD MD
• Email: maja.guberina@uk-essen.de
• Phone: 0201 723 83121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adjuvant darovasertib and crizotinib in high-risk non-metastatic uveal melanoma

  Researchers are testing whether adding darovasertib and crizotinib after local eye tumor treatment can help prevent recurrence in people with high-risk, non-metastatic uveal melanoma.

  Recruiting at 4 sites Phase 3 IDEAYA Biosciences · Scottsdale, Arizona and 12 other locations · NCT07804186

• Neoadjuvant immunotherapy for high-risk eye melanoma

  This trial tests whether giving nivolumab and ipilimumab before surgery is safe and feasible for adults with high-risk uveal melanoma.

  Recruiting Phase 1 Herlev Hospital · Herlev, Herlev · NCT07501117

• Immune response after delivering melphalan directly to the liver for uveal (eye) melanoma that has spread to the liver.

  This test will see how the liver's immune system responds when people with uveal melanoma that has spread to the liver receive melphalan delivered directly to the liver through percutaneous hepatic perfusion.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT07364474

• Adding IL-2 to tebentafusp to overcome resistance in uveal melanoma

  This trial tests whether giving interleukin‑2 (IL‑2) together with tebentafusp can help people with HLA‑A*02:01 metastatic uveal melanoma who progressed on tebentafusp.

  Recruiting Phase 1/2 St Vincent's Hospital, Sydney · Sydney, New South Wales and 1 other locations · NCT07063875

• Darovasertib before local treatment for primary uveal melanoma

  This trial tests whether giving darovasertib before surgery or radiation helps people with primary non-metastatic uveal melanoma.

  Recruiting at 25 sites Phase 3 IDEAYA Biosciences · Scottsdale, Arizona and 93 other locations · NCT07015190

• Using quisinostat to prevent uveal melanoma from spreading

  This study is testing if a drug called quisinostat can help prevent uveal melanoma from spreading in patients who are at high risk after their initial treatment.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06932757

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.